Israel’s Silexion Therapeutics (see here previously) received Israeli Ministry of Health approval to initiate a Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer, marking advancement to clinical-stage development. SIL204 targets a range of common KRAS mutations. https://www.stocktitan.net/news/SLXN/silexion-therapeutics-receives-approval-from-israeli-ministry-of-8p7b37yrir10.html

Israel’s Silexion reported here in April that its SIL-204 reduced pancreatic tumors. Latest studies show it also works on lung cancer. Its silencing of KRAS protein mutations achieved unprecedented inhibition rates of up to 97% in pancreatic cancer cells and … Continue reading →

Israel’s Silexion Therapeutics reported that its SIL-204 pancreatic cancer treatment effectively reduces primary tumor growth and secondary cancer spread. Silexion ‘s first generation LODER treatment already had good results in Phase 2 trials on “simple” cancers. https://silexion.com/wp-content/uploads/2025/02/silexion-therapeutics-announces-completion-of1.pdf